Media

BONESUPPORT HOLDING AB PUBLISHES ANNUAL REPORT 2024

Oncopeptides – New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients

Article on Intervacc’s Streptococcus suis study published in the journal Vaccine

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

Pretzel Therapeutics Announces Publication in Nature unveiling discovery of novel small molecule activators for the treatment of POLG disorders and other conditions related to mtDNA depletion

BONESUPPORT HOLDING AB (publ) – Information on the impact of tariffs in connection with the company’s import into the United States

Intervacc publishes the 2024 Annual Report

Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise

SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy